PubMed:35293348
Annnotations
Inflammaging
{"project":"Inflammaging","denotations":[{"id":"T1","span":{"begin":0,"end":132},"obj":"Sentence"},{"id":"T2","span":{"begin":133,"end":144},"obj":"Sentence"},{"id":"T3","span":{"begin":145,"end":264},"obj":"Sentence"},{"id":"T4","span":{"begin":265,"end":275},"obj":"Sentence"},{"id":"T5","span":{"begin":276,"end":444},"obj":"Sentence"},{"id":"T6","span":{"begin":445,"end":453},"obj":"Sentence"},{"id":"T7","span":{"begin":454,"end":557},"obj":"Sentence"},{"id":"T8","span":{"begin":558,"end":772},"obj":"Sentence"},{"id":"T9","span":{"begin":773,"end":827},"obj":"Sentence"},{"id":"T10","span":{"begin":828,"end":991},"obj":"Sentence"},{"id":"T11","span":{"begin":992,"end":1098},"obj":"Sentence"},{"id":"T12","span":{"begin":1099,"end":1176},"obj":"Sentence"},{"id":"T13","span":{"begin":1177,"end":1288},"obj":"Sentence"},{"id":"T14","span":{"begin":1289,"end":1413},"obj":"Sentence"},{"id":"T15","span":{"begin":1414,"end":1540},"obj":"Sentence"},{"id":"T16","span":{"begin":1541,"end":1687},"obj":"Sentence"},{"id":"T17","span":{"begin":1688,"end":1699},"obj":"Sentence"},{"id":"T18","span":{"begin":1700,"end":1886},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":132},"obj":"Sentence"},{"id":"T2","span":{"begin":133,"end":144},"obj":"Sentence"},{"id":"T3","span":{"begin":145,"end":264},"obj":"Sentence"},{"id":"T4","span":{"begin":265,"end":275},"obj":"Sentence"},{"id":"T5","span":{"begin":276,"end":444},"obj":"Sentence"},{"id":"T6","span":{"begin":445,"end":453},"obj":"Sentence"},{"id":"T7","span":{"begin":454,"end":557},"obj":"Sentence"},{"id":"T8","span":{"begin":558,"end":772},"obj":"Sentence"},{"id":"T9","span":{"begin":773,"end":827},"obj":"Sentence"},{"id":"T10","span":{"begin":828,"end":991},"obj":"Sentence"},{"id":"T11","span":{"begin":992,"end":1098},"obj":"Sentence"},{"id":"T12","span":{"begin":1099,"end":1176},"obj":"Sentence"},{"id":"T13","span":{"begin":1177,"end":1288},"obj":"Sentence"},{"id":"T14","span":{"begin":1289,"end":1413},"obj":"Sentence"},{"id":"T15","span":{"begin":1414,"end":1540},"obj":"Sentence"},{"id":"T16","span":{"begin":1541,"end":1687},"obj":"Sentence"},{"id":"T17","span":{"begin":1688,"end":1699},"obj":"Sentence"},{"id":"T18","span":{"begin":1700,"end":1886},"obj":"Sentence"}],"text":"Immunomodulatory Effects of Omega-3 Fatty Acids in Patients with Differentiated Thyroid Cancer Before or After Radioiodine Ablation.\nBACKGROUND: Thyroid cancer and radioactive iodine (RAI) ablation for postsurgical management may lead to uncontrolled inflammation.\nOBJECTIVE: This study was intended to assess the prophylactic and therapeutic immunomodulatory effects of omega-3 fatty acids in patients with differentiated thyroid cancer (DTC).\nMETHODS: A total of 85 patients with DTC were allocated into two groups based on RAI dosage after thyroidectomy. Patients in each group were randomly distributed into three subgroups: G1 with RAI ablation only, G2 treated with omega-3 for 30 days before RAI ablation, and G3 treated with omega-3 for 30 days after RAI ablation. Fifteen healthy individuals were included as controls. Serum cytokine levels including IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17A, IL-17F, IL-21, IL-22, TNF-α and IFN-γ were determined by cytometric bead assay.\nRESULTS: IL-4, IL-6, IL-21 and IL-22 levels in patients with DTC were higher than in the healthy controls. Regardless of RAI dosage, IL-6 showed an increasing trend after RAI ablation. IL-4, IL-22, and IL-17A remained at considerably higher levels than in the healthy controls after RAI ablation. Within-group comparisons showed a significant reduction in Th1+Th17/Th2+Th22 ratio in G2 patients 1 week after RAI ablation. Between-group comparisons showed increased IL-10 levels in G3 compared with G1 patients one week after high-dose RAI ablation. In G3, Th1+Th17/Th2+Th22 and Th1+Th17/Th2+Th9+Th22 ratios were remarkably lesser than in G2 patients 1 month after intermediate-dose RAI ablation.\nCONCLUSION: Our results showed better anti-inflammatory effects of omega-3 when it was used therapeutically after RAI ablation in patients with DTC than when it was used prophylactically before RAI."}
yangbin123xm_800_3
{"project":"yangbin123xm_800_3","denotations":[{"id":"T1","span":{"begin":65,"end":94},"obj":"DP"},{"id":"T10","span":{"begin":1755,"end":1762},"obj":"CI"},{"id":"T11","span":{"begin":733,"end":740},"obj":"CI"},{"id":"T2","span":{"begin":408,"end":437},"obj":"DP"},{"id":"T3","span":{"begin":439,"end":442},"obj":"DP"},{"id":"T4","span":{"begin":482,"end":485},"obj":"DP"},{"id":"T5","span":{"begin":1053,"end":1056},"obj":"DP"},{"id":"T6","span":{"begin":1832,"end":1835},"obj":"DP"},{"id":"T8","span":{"begin":371,"end":390},"obj":"CI"},{"id":"T9","span":{"begin":672,"end":679},"obj":"CI"},{"id":"T12","span":{"begin":28,"end":47},"obj":"CI"},{"id":"T13","span":{"begin":145,"end":159},"obj":"DP"}],"text":"Immunomodulatory Effects of Omega-3 Fatty Acids in Patients with Differentiated Thyroid Cancer Before or After Radioiodine Ablation.\nBACKGROUND: Thyroid cancer and radioactive iodine (RAI) ablation for postsurgical management may lead to uncontrolled inflammation.\nOBJECTIVE: This study was intended to assess the prophylactic and therapeutic immunomodulatory effects of omega-3 fatty acids in patients with differentiated thyroid cancer (DTC).\nMETHODS: A total of 85 patients with DTC were allocated into two groups based on RAI dosage after thyroidectomy. Patients in each group were randomly distributed into three subgroups: G1 with RAI ablation only, G2 treated with omega-3 for 30 days before RAI ablation, and G3 treated with omega-3 for 30 days after RAI ablation. Fifteen healthy individuals were included as controls. Serum cytokine levels including IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17A, IL-17F, IL-21, IL-22, TNF-α and IFN-γ were determined by cytometric bead assay.\nRESULTS: IL-4, IL-6, IL-21 and IL-22 levels in patients with DTC were higher than in the healthy controls. Regardless of RAI dosage, IL-6 showed an increasing trend after RAI ablation. IL-4, IL-22, and IL-17A remained at considerably higher levels than in the healthy controls after RAI ablation. Within-group comparisons showed a significant reduction in Th1+Th17/Th2+Th22 ratio in G2 patients 1 week after RAI ablation. Between-group comparisons showed increased IL-10 levels in G3 compared with G1 patients one week after high-dose RAI ablation. In G3, Th1+Th17/Th2+Th22 and Th1+Th17/Th2+Th9+Th22 ratios were remarkably lesser than in G2 patients 1 month after intermediate-dose RAI ablation.\nCONCLUSION: Our results showed better anti-inflammatory effects of omega-3 when it was used therapeutically after RAI ablation in patients with DTC than when it was used prophylactically before RAI."}
chenxin_473849_800_3
{"project":"chenxin_473849_800_3","denotations":[{"id":"T1","span":{"begin":28,"end":47},"obj":"CI"},{"id":"T10","span":{"begin":439,"end":442},"obj":"DP"},{"id":"T11","span":{"begin":482,"end":485},"obj":"DP"},{"id":"T12","span":{"begin":1053,"end":1056},"obj":"DP"},{"id":"T13","span":{"begin":1832,"end":1835},"obj":"DP"},{"id":"T2","span":{"begin":371,"end":390},"obj":"CI"},{"id":"T3","span":{"begin":672,"end":679},"obj":"CI"},{"id":"T5","span":{"begin":733,"end":740},"obj":"CI"},{"id":"T6","span":{"begin":1755,"end":1762},"obj":"CI"},{"id":"T7","span":{"begin":145,"end":159},"obj":"DP"},{"id":"T14","span":{"begin":408,"end":437},"obj":"DP"},{"id":"T15","span":{"begin":65,"end":94},"obj":"DP"}],"text":"Immunomodulatory Effects of Omega-3 Fatty Acids in Patients with Differentiated Thyroid Cancer Before or After Radioiodine Ablation.\nBACKGROUND: Thyroid cancer and radioactive iodine (RAI) ablation for postsurgical management may lead to uncontrolled inflammation.\nOBJECTIVE: This study was intended to assess the prophylactic and therapeutic immunomodulatory effects of omega-3 fatty acids in patients with differentiated thyroid cancer (DTC).\nMETHODS: A total of 85 patients with DTC were allocated into two groups based on RAI dosage after thyroidectomy. Patients in each group were randomly distributed into three subgroups: G1 with RAI ablation only, G2 treated with omega-3 for 30 days before RAI ablation, and G3 treated with omega-3 for 30 days after RAI ablation. Fifteen healthy individuals were included as controls. Serum cytokine levels including IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17A, IL-17F, IL-21, IL-22, TNF-α and IFN-γ were determined by cytometric bead assay.\nRESULTS: IL-4, IL-6, IL-21 and IL-22 levels in patients with DTC were higher than in the healthy controls. Regardless of RAI dosage, IL-6 showed an increasing trend after RAI ablation. IL-4, IL-22, and IL-17A remained at considerably higher levels than in the healthy controls after RAI ablation. Within-group comparisons showed a significant reduction in Th1+Th17/Th2+Th22 ratio in G2 patients 1 week after RAI ablation. Between-group comparisons showed increased IL-10 levels in G3 compared with G1 patients one week after high-dose RAI ablation. In G3, Th1+Th17/Th2+Th22 and Th1+Th17/Th2+Th9+Th22 ratios were remarkably lesser than in G2 patients 1 month after intermediate-dose RAI ablation.\nCONCLUSION: Our results showed better anti-inflammatory effects of omega-3 when it was used therapeutically after RAI ablation in patients with DTC than when it was used prophylactically before RAI."}